azacitidine has been researched along with enasidenib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K | 1 |
| Hoffmann, M; Surapaneni, S; Tong, Z; Yao, S; Yerramilli, U; Young, JD | 1 |
| Estey, EH; Percival, MM | 1 |
| Naoe, T | 1 |
| Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B | 1 |
| Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Alvarado, Y; Borthakur, G; Carraway, H; Chien, K; Daver, N; Dezern, A; DiNardo, CD; Garcia-Manero, G; Hammond, D; Kadia, T; Kantarjian, HM; Lachowiez, C; Loghavi, S; Maiti, A; Masarova, L; Montalban-Bravo, G; Patel, B; Ravandi, F; Roboz, G; Sasaki, K; Sekeres, M; Short, NJ; Sukkur, A; Takahashi, K; Venugopal, S; Wang, X | 1 |
| Aiman, W; Akerman, MJ; Ali, MA; Anwar, MS; Anwer, F; Basit, MA; Dhanesar, G; Faisal, MS; Hassan, M; Jamil, T; Maroules, M; Omar, Z; Shafique, Z; Suleman, M | 1 |
4 review(s) available for azacitidine and enasidenib
| Article | Year |
|---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
Topics: Azacitidine; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation | 2023 |
1 trial(s) available for azacitidine and enasidenib
| Article | Year |
|---|---|
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines | 2021 |
5 other study(ies) available for azacitidine and enasidenib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines | 2017 |
Topics: Aminopyridines; Animals; Azacitidine; Cell Line; Humans; Isocitrate Dehydrogenase; Nucleoside Transport Proteins; Triazines; Xenopus laevis | 2019 |
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines | 2021 |
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Topics: Aged; Azacitidine; Humans; Isocitrate Dehydrogenase; Mutation; Myelodysplastic Syndromes | 2023 |